Skip navigation

Action Plan Strategies for Long-Term Success

January 22-23, 2019
  • Alexandria, VA
Industry Update —
In-depth coverage on industry implications of the FDA’s Biosimilar Action Plan on Balancing Innovation and Competition
Navigate Evolving Regulations  •  Educate Stakeholders
Accelerate Market Access

As more biosimilar products continue to be added to the FDA pipeline, it is critical that pharmaceutical companies develop strategies to navigate evolving regulations, educate stakeholders in cross functional areas and execute long-term decisions to prepare for success. At CBI’s 14th Biosimilars Summit, you’ll gain insights from industry experts on the tools and strategies needed to prepare for the current changes impacting all elements of the healthcare industry.

Hear insights from key stakeholders including biosimilar and innovator pharmaceutical manufacturers, payers, providers and patient advocates addressing everything from navigating impending regulations, determining optimal pricing models, accelerating market access strategies and executing strategic, long term decisions to mitigate risk and build for success.

Join CBI’s 14th Biosimilars Summit and explore the current global climate for biosimilars, evaluate competition and benchmark with industry peers on how to navigate the changing regulations and landscape of the biosimilars market.


  • The FDA’s Biosimilar Action Plan — Streamlining for Success
  • Leveraging Real-World Evidence in the U.S. Biosimilars Market
  • The Latest in Biosimilar News
  • Optimizing the Value of Employers
  • Shrinking the Education Gap on Biosimilars
  • Medicare Part B for Biosimilars
  • Commercial Considerations and Market Access
  • Opportunities for Global Development of Biosimilars